Shopping Cart
Remove All
Your shopping cart is currently empty
(S)-α-Methylbenzyl ricinoleamide is a fatty acid amide derived from ricinoleic acid and methyl benzylamine. It demonstrates potent growth inhibition of glioma (U251), breast (MCF-7), ovarian (NCI-ADR/RES and OVCAR-3), kidney (786-0), non-small cell lung (NCI-H460), and prostate (PC-3) cancer cells with a mean GI50 value of 6.9 μM.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $113 | 35 days | 35 days | |
| 5 mg | $493 | 35 days | 35 days | |
| 10 mg | $862 | 35 days | 35 days | |
| 25 mg | $1,920 | 35 days | 35 days |
| Description | (S)-α-Methylbenzyl ricinoleamide is a fatty acid amide derived from ricinoleic acid and methyl benzylamine. It demonstrates potent growth inhibition of glioma (U251), breast (MCF-7), ovarian (NCI-ADR/RES and OVCAR-3), kidney (786-0), non-small cell lung (NCI-H460), and prostate (PC-3) cancer cells with a mean GI50 value of 6.9 μM. |
| Molecular Weight | 401.63 |
| Formula | C26H43NO2 |
| Cas No. | 1246776-22-6 |
| Relative Density. | no data available |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMF: 30 mg/mL (74.7 mM), Sonication is recommended. Ethanol:PBS (pH 7.2) (1:3): 0.25 mg/mL (0.62 mM), Sonication is recommended. DMSO: 25 mg/mL (62.25 mM), Sonication is recommended. Ethanol: 30 mg/mL (74.7 mM), Sonication is recommended. |
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.